JP2005520778A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520778A5
JP2005520778A5 JP2003510042A JP2003510042A JP2005520778A5 JP 2005520778 A5 JP2005520778 A5 JP 2005520778A5 JP 2003510042 A JP2003510042 A JP 2003510042A JP 2003510042 A JP2003510042 A JP 2003510042A JP 2005520778 A5 JP2005520778 A5 JP 2005520778A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydroxyoxymorphone
pharmaceutically acceptable
acceptable salt
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003510042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021398 external-priority patent/WO2003004031A1/en
Publication of JP2005520778A publication Critical patent/JP2005520778A/ja
Publication of JP2005520778A5 publication Critical patent/JP2005520778A5/ja
Pending legal-status Critical Current

Links

JP2003510042A 2001-07-06 2002-07-03 鎮痛薬として使用するための6−ヒドロキシ−オキシモルホンの非経口投与 Pending JP2005520778A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30335701P 2001-07-06 2001-07-06
US32943201P 2001-10-15 2001-10-15
US32944501P 2001-10-15 2001-10-15
US32944401P 2001-10-15 2001-10-15
PCT/US2002/021398 WO2003004031A1 (en) 2001-07-06 2002-07-03 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic

Publications (2)

Publication Number Publication Date
JP2005520778A JP2005520778A (ja) 2005-07-14
JP2005520778A5 true JP2005520778A5 (enExample) 2006-01-05

Family

ID=27501826

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003510042A Pending JP2005520778A (ja) 2001-07-06 2002-07-03 鎮痛薬として使用するための6−ヒドロキシ−オキシモルホンの非経口投与
JP2003510041A Expired - Fee Related JP4440635B2 (ja) 2001-07-06 2002-07-03 オキシモルホン放出制御性処方物
JP2003510043A Pending JP2005515966A (ja) 2001-07-06 2002-07-03 鎮痛薬としての使用のための6−ヒドロキシ−オキシモルホンの経口投与
JP2009044920A Pending JP2009114209A (ja) 2001-07-06 2009-02-26 オキシモルホン放出制御性処方物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2003510041A Expired - Fee Related JP4440635B2 (ja) 2001-07-06 2002-07-03 オキシモルホン放出制御性処方物
JP2003510043A Pending JP2005515966A (ja) 2001-07-06 2002-07-03 鎮痛薬としての使用のための6−ヒドロキシ−オキシモルホンの経口投与
JP2009044920A Pending JP2009114209A (ja) 2001-07-06 2009-02-26 オキシモルホン放出制御性処方物

Country Status (13)

Country Link
US (13) US20030130297A1 (enExample)
EP (4) EP1404333A1 (enExample)
JP (4) JP2005520778A (enExample)
KR (1) KR20030034171A (enExample)
CN (3) CN1610551A (enExample)
AT (1) ATE359077T1 (enExample)
AU (3) AU2002320309B2 (enExample)
BR (1) BR0205721A (enExample)
CA (3) CA2452872A1 (enExample)
DE (1) DE60219478T2 (enExample)
ES (1) ES2284888T3 (enExample)
NO (1) NO20031018L (enExample)
WO (3) WO2003004031A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1404333A1 (en) * 2001-07-06 2004-04-07 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CN1934141A (zh) * 2004-03-22 2007-03-21 纳幕尔杜邦公司 用于低voc涂料的原酸酯保护的多元醇
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
EP2719378B1 (en) 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
CN101578095A (zh) * 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的缓释制剂
CA2652981C (en) * 2006-10-10 2012-05-01 Penwest Pharmaceuticals Co. Robust sustained release formulations
CN101578094A (zh) * 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的羟吗啡酮缓释制剂及其使用方法
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) * 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
DE102009060332B4 (de) * 2009-12-23 2017-04-06 Telefónica O2 Germany GmbH & Co. OHG Verfahren und Vorrichtung zum Bereitstellen eines Telekommunikationsdienstes
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015015146A1 (en) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
ES2862209T3 (es) * 2017-07-20 2021-10-07 Intas Pharmaceuticals Ltd Composiciones orales sólidas de liberación prolongada no pulsátil que contienen betahistina

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591431A (en) * 1897-10-12 Coupling for traps and pipes
US458349A (en) * 1891-08-25 Hose-coupling
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
DE1517480A1 (de) 1962-11-16 1969-05-22 Permutit Co Ltd Vorrichtung zum Regenerieren von Ionenaustauschern,insbesondere fuer die Wasserenthaertung
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3456049A (en) * 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
IL26896A (en) 1966-01-19 1970-11-30 Endo Lab 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US3879555A (en) * 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
JPS5936110B2 (ja) * 1976-11-01 1984-09-01 株式会社日立製作所 二重点火式点火装置
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4489080A (en) * 1981-06-26 1984-12-18 The Upjohn Company Process for analgesic treatment
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4486436A (en) 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4587249A (en) * 1982-07-22 1986-05-06 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4464376A (en) * 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
ZA835324B (en) 1982-07-22 1984-09-26 Abraham Sunshine Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4656177A (en) * 1982-07-22 1987-04-07 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4777174A (en) 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4521401A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of quinidine
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
US4521402A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of hydrazine
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4479956A (en) 1983-04-26 1984-10-30 Analgeic Associates Analgesic compositions comprising propiram and methods of using same
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4599114A (en) * 1985-02-11 1986-07-08 Atkinson George K Treatment of titanium dioxide and other pigments to improve dispersibility
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
DE3822095A1 (de) 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5169639A (en) 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5226331A (en) * 1991-10-03 1993-07-13 General Electric Company Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1993017673A1 (en) 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
PT706377E (pt) 1994-04-25 2002-05-31 Mendell Co Inc Edward Excipiente de libertacao
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9426407D0 (en) 1994-12-30 1995-03-01 Sandoz Ltd Improvements in or relating to organic compounds
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5567754A (en) 1995-08-23 1996-10-22 Kerr-Mcgee Corporation Pigments with improved dispersibility in thermoplastic resins
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JP3134187B2 (ja) 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
CA2461157C (en) 1996-04-18 2007-08-28 Penwest Pharmaceutical Co. Sustained release heterodisperse hydrogel systems - amorphous drugs
WO1998000143A1 (en) 1996-06-28 1998-01-08 Knoll Pharmaceutical Company Slow release pharmaceutical compositions and methods of making same
JP3148256B2 (ja) * 1996-07-08 2001-03-19 エドワード メンデル カンパニー.,インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
CA2305183C (en) 1997-10-03 2008-09-23 The Governors Of The University Of Alberta Postsurgical treatment with dichloroacetate
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6102358A (en) * 1997-11-03 2000-08-15 Mcleary; Joseph Butler Counterpoise and mounting clamp for a musical drum
BR9813826A (pt) 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP2266564B1 (en) * 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
GB9816723D0 (en) 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
DE29818454U1 (de) 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
RO120817B1 (ro) 1999-04-13 2006-08-30 Beecham Pharmaceuticals (Pte) Limited Compoziţie farmaceutică cu eliberare modificată şi utilizarea acesteia
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
WO2001008661A2 (en) 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ,インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
ATE391495T1 (de) 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス.エイ. 制御放出ヒドロコドン処方
PT1242055E (pt) 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
EP1248594B1 (en) * 2000-01-19 2005-12-14 Mannkind Corporation Multi-spike release formulation for drug delivery
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU782523B2 (en) 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20020032581A1 (en) 2000-07-17 2002-03-14 Reitberg Donald P. Single-patient drug trials used with accumulated database: risk of habituation
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
EP1315533A4 (en) 2000-08-15 2007-06-27 Univ Kentucky Res Found PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION
CA2423558A1 (en) 2000-10-03 2002-04-11 Penwest Pharmaceuticals Company Delivery system for multi-pharmaceutical active materials at various release rates
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ, インコーポレイティド 乱用防止制御放出オピオイド投薬形態
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
EP1404333A1 (en) * 2001-07-06 2004-04-07 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
CA2454328C (en) 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
BR0212020A (pt) 2001-08-06 2005-08-16 Euro Celtique Sa Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
WO2003013479A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
WO2003015531A2 (en) 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US20030158264A1 (en) 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
ATE408407T1 (de) 2002-02-27 2008-10-15 Ab Science Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
JP4790219B2 (ja) 2002-03-26 2011-10-12 ユーロ−セルティーク エス.エイ. 徐放性ゲルコーティング組成物
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
CA2617164A1 (en) 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
PT1931315E (pt) 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
WO2007078895A2 (en) 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080119501A1 (en) 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20080085304A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
CN101578094A (zh) 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的羟吗啡酮缓释制剂及其使用方法
CA2652981C (en) 2006-10-10 2012-05-01 Penwest Pharmaceuticals Co. Robust sustained release formulations
CN101578095A (zh) 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的缓释制剂
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20080318993A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment

Similar Documents

Publication Publication Date Title
JP2005520778A5 (enExample)
JP2005515966A5 (enExample)
JP2006501240A5 (enExample)
JP2018513188A5 (enExample)
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
JP2002532392A5 (enExample)
JP2007515469A5 (enExample)
WO2004043389B1 (en) Methods of treating cancer and related methods
KR101900520B1 (ko) 복합 조성물
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
JP2007507538A5 (enExample)
WO2003080022A3 (en) Analgesics for nasal administration
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
JP2002528502A5 (enExample)
JP2025148449A5 (enExample)
JP2006514681A5 (enExample)
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
JP2008517991A5 (enExample)
RU2152215C1 (ru) Применение ропивакаина при изготовлении фармацевтического препарата с анальгезирующим действием с минимальной моторной блокадой
JP2005529152A5 (enExample)
CA2482687A1 (en) Treatment of mesothelioma
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
KR930702985A (ko) 식도암의 치료
JP2002529515A5 (enExample)